Piper Sandler Downgrades NovoCure to Neutral, Lowers Price Target to $70
Piper Sandler analyst Jason Bednar downgrades NovoCure (NASDAQ:NVCR) from Overweight to Neutral and lowers the price target from $90 to $70.
Raymond James Downgrades Continental Resources to Market Perform
Raymond James analyst John Freeman downgrades Continental Resources (NYSE:CLR) from Outperform to Market Perform.
BMO Capital Downgrades Green Plains to Market Perform, Lowers Price Target to $31
BMO Capital analyst Kenneth Zaslow downgrades Green Plains (NASDAQ:GPRE) from Outperform to Market Perform and lowers the price target from $45 to $31.
SVB Leerink Downgrades AVEO Pharmaceuticals to Market Perform
SVB Leerink analyst Andrew Berens downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Outperform to Market Perform.
Analyst Downgrades Immunic After Lack of Details Drive Uncertainty
SVB Leerink has downgraded Immunic Inc (NASDAQ:IMUX) to Market Perform from Outperform following disappointing initial data from the highly anticipated Phase 1b proof-of-concept…
Raymond James Downgrades US Homebuilders On Mortgage Rate Hike
Raymond James analyst Buck Horne lowered the rating on the shares of KB Home (NYSE:KBH), Lennar Corp (NYSE:LEN), M.D.C. Holdings Inc (NYSE:MDC), PulteGroup Inc (NYSE:PHM), and Toll Brothers…
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline
SVB Leerink downgraded Zymeworks Inc (NASDAQ:ZYME) to Market Perform with a price target of $8, down from $19 following the recent divestiture of…
Raymond James Downgrades PulteGroup to Market Perform
Raymond James analyst Buck Horne downgrades PulteGroup (NYSE:PHM) from Strong Buy to Market Perform.
JP Morgan Downgrades Robert Half International to Neutral, Announces $76 Price Target
JP Morgan analyst Andrew Steinerman downgrades Robert Half International (NYSE:RHI) from Overweight to Neutral and announces $76 price target.